GE Healthcare Announces CE Marking for Its Breast Tomosynthesis Solution, SenoClaire
7/16/2013 10:27:13 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
BUC, France--(BUSINESS WIRE)--GE Healthcare (NYSE: GE), hailed a new era for breast imaging today as it announced CE marking for SenoClaire*, GE’s new generation of breast tomosynthesis solution designed with a three-dimensional imaging technology. Powered by ASiR*DBT 1, SenoClaire technology uses a low-dose short X-ray sweep around the positioned breast with nine exposures acquired with a “step-and-shoot” method, removing the potential motion from images.
Help employers find you! Check out all the jobs and post your resume.
comments powered by